Effect of Cladribine Treatment on Microglial Activation in the CNS

Korábbi kezelés

• Corticosteroid treatment within 4 weeks of imaging
• Exposure to experimental radiation in the past 12 months such that radiodosimetry limits would be exceeded by participating in this study.
• Intolerance to previous PET scans; i.e. previous hypersensitivity reactions to any PET ligand or imaging agent or failure to participate in and comply with previous PET scans.
• Patients with previous alemtuzumab administration
• Patients with less than 1 month since previous administration of other disease modifying therapy

Más betegség

• Patients with other neurodegenerative disease than MS
• Patients with human immunodeficiency virus (HIV).
• Patients with active chronic infection (tuberculosis or hepatitis).
• Patients with active malignancy.
• Patients with claustrophobia, or a history of moderate to severe anxiety disorder or panic attacks (which could potentially lead to preterm termination of the imaging)

Laborértékek

• Abnormal lymphocyte counts
• Patients with moderate or severe renal impairment (creatinine clearance <60 mL/min)
• Patients with less than 6 months since previous administration of ocrelizumab or rituximab (or with abnormal B-cell counts)

Egyéb

• Patients that are pregnant or breast-feeding
• Patients with significant abnormal findings other than MS in the screening MRI.
• Contraindication to PET scan investigations

• Signing the informed consent form
• Cladribine treatment is planned and indicated and is according to label
• 45-55 years of age at the time of signing the research informed consent form
• RRMS diagnosis in accordance with McDonald 2017 criteria